CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases

@inproceedings{Khan2016CRISPRCas9TA,
  title={CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases},
  author={Faheem Ahmed Khan and Nuruliarizki Shinta Pandupuspitasari and Huang Chun-jie and Zhou Ao and Muhammad Sobrun Jamil Jamal and Ali Zohaib and Farhan Ahmed Khan and Muthia Raihana Hakim and Zhang Shujun},
  booktitle={Oncotarget},
  year={2016}
}
Cancer is caused by a series of alterations in genome and epigenome mostly resulting in activation of oncogenes or inactivation of cancer suppressor genes. Genetic engineering has become pivotal in the treatment of cancer and other genetic diseases, especially the formerly-niche use of clustered regularly interspaced short palindromic repeats (CRISPR) associated with Cas9. In defining its superior use, we have followed the recent advances that have been made in producing CRISPR/Cas9 as a… CONTINUE READING
5
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Gene Editing in Clinical Practice: Where are We?

  • Indian Journal of Clinical Biochemistry
  • 2018

References

Publications referenced by this paper.
SHOWING 1-10 OF 75 REFERENCES

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Keeping CRISPR/Cas on-Target.

  • Current issues in molecular biology
  • 2016
VIEW 2 EXCERPTS